Aegerion Pharmaceuticals, Inc.  

(Public, NASDAQ:AEGR)   Watch this stock  
Find more results for AEGR
After Hours: 2.20 +0.23 (11.68%)
Nov 29, 7:59PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 1.23 - 10.85
Open     -
Vol / Avg. 0.00/249,400.00
Mkt cap 56.69M
P/E     -
Div/yield     -
EPS -5.97
Shares 29.55M
Beta 0.50
Inst. own 85%

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -75.07% -30.57%
Operating margin -53.03% -18.84%
EBITD margin - -9.67%
Return on average assets -29.21% -17.33%
Return on average equity - -53.17%
Employees 318 -
CDP Score - -


1 Main St Ste 800
CAMBRIDGE, MA 02142-1531
United States - Map
+1-617-5007867 (Phone)
+1-302-6365454 (Fax)

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor. Lomitapide received marketing approval under the brand name Juxtapid (lomitapide) capsules from the United States Food and Drug Administration (FDA) as an adjunct to a low-fat diet and other lipid-lowering treatments. It also received marketing authorization for lomitapide in the European Union (EU) under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA) as a treatment for HoFH in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor. Metreleptin is marketed in the United States under the brand name MYALEPT (metreleptin) for injection (MYALEPT).